International journal of radiation oncology, biology, physics
-
Int. J. Radiat. Oncol. Biol. Phys. · Oct 2010
The megavoltage radiation therapy in treatment of patients with advanced or difficult giant cell tumors of bone.
To assess the outcomes of radiotherapy, in terms of local control and treatment complications, of advanced or difficult giant cell tumors of bone (GCTB) that could not be treated by surgery. ⋯ GCTB can be safely and effectively treated with megavoltage radiotherapy with local control rate >80% at 5 years. Our study confirms that radiotherapy of GCTB offers an alternative to difficult or complex surgery and may be an option of choice in the treatment of inoperable patients.
-
Int. J. Radiat. Oncol. Biol. Phys. · Oct 2010
Stereotactic radiosurgery for treatment of spinal metastases recurring in close proximity to previously irradiated spinal cord.
As the spinal cord tolerance often precludes reirradiation with conventional techniques, local recurrence within a previously irradiated field presents a treatment challenge. ⋯ SRS is safe and effective in the treatment of spinal metastases recurring in previously irradiated fields. Tumor recurrence within 12 months may correlate with biologic aggressiveness and require higher SRS doses (SSED >15 Gy(10)). Further research is needed to define the partial volume retreatment tolerance of the spinal cord and the optimal target dose.
-
Int. J. Radiat. Oncol. Biol. Phys. · Oct 2010
Comparative StudyDecreasing temporal lobe dose with five-field intensity-modulated radiotherapy for treatment of pituitary macroadenomas.
To compare temporal lobe dose delivered by three pituitary macroadenoma irradiation techniques: three-field three-dimensional conformal radiotherapy (3D-CRT), three-field intensity-modulated radiotherapy (3F IMRT), and a proposed novel alternative of five-field IMRT (5F IMRT). ⋯ Five-field IMRT irradiation technique results in a statistically significant decrease in the dose to the temporal lobes and may thus help prevent neurocognitive sequelae in irradiated pituitary macroadenoma patients.
-
Int. J. Radiat. Oncol. Biol. Phys. · Oct 2010
Biochemical disease-free rate and toxicity for men treated with iodine-125 prostate brachytherapy with d(90) ≥180 Gy.
Iodine-125 ((125)I) prostate brachytherapy is planned with a prescribed dose of 145 Gy and minimal dose received by 90% of the prostate (D(90)) of 120-125% (174-181 Gy). We examined the clinical outcomes and toxicity profile of men receiving a D(90) (isodose enclosing 90% of the prostate) of ≥180 Gy. ⋯ A D(90) of ≥180 Gy is associated with excellent biochemical disease-free survival and acceptable toxicity.
-
Int. J. Radiat. Oncol. Biol. Phys. · Oct 2010
Multidisciplinary team contributions within a dedicated outpatient palliative radiotherapy clinic: a prospective descriptive study.
Patients with bone metastases may experience pain, fatigue, and decreased mobility. Multiple medications for analgesia are often required, each with attendant side effects. Although palliative-intent radiotherapy (RT) is effective in decreasing pain, additional supportive care interventions may be overlooked. Our objective was to describe the feasibility of multidisciplinary assessment of patients with symptomatic bone metastases attending a dedicated outpatient palliative RT clinic. ⋯ Systematic screening of this population revealed previously unmet needs, addressed in the form of custom verbal and written recommendations. Multidisciplinary assessment is associated with a high number of recommendations and decreased symptom distress. Our findings lend strong support to the routine assessment by multiple supportive care professionals for patients with advanced cancer being considered for palliative RT.